Articles tagged "Immunosuppression"

2022 American Transplant Congress
Low Fixed Tacrolimus Starting Dose and the Correlation with Renal Allograft Rejection
R. Davoudi, E. Kitchel, S. Lee, T. Tan, T. Sievers, S. Bunnapradist
David Geffen School of Medicine, Los Angeles, CA
*Purpose: Achieving a tacrolimus therapeutic trough concentration (C0) by post-operative day (POD) 3-7 has been associated with a reduced risk for rejection. Although FDA prescribing…
2022 American Transplant Congress
Impact of Early Calcineurin-Inhibitor Conversion to Belatacept on Renal Allograft Function in a Steroid-Free Maintenance Regimen: Results from a Randomized Controlled Study
I. Tawhari¹, P. Hallak¹, S. Hartzell², V. Mas³, P. Cravedi², J. Leventhal¹, J. Ansari¹, L. Gallon¹
¹Northwestern University, Chicago, IL, ²Mount Sinai, New York, NY, ³University of Maryland, Baltimore, MD
*Purpose: Belatacept (Bela) was developed to minimize nephrotoxicity and cardiovascular risk associated with Calcineurin inhibitors (CNIs). Early steroid withdrawal (ESW) and simultaneous CNI avoidance (CNIA)…
2022 American Transplant Congress
Covid-19 Vaccination Response In Tacrolimus Treated Kidney Transplant Recipients With And Without Mycophenolate Mofetil: Follow-up Of A Randomized Controlled Trial
Z. Al Fatly¹, M. G. Betjes¹, A. L. Messchendorp², J. S. Sanders², M. E. Reinders¹, M. M. Kho¹, A. E. de Weerd¹
¹Department of Internal Medicine, Erasmus MC Transplant Institute University Medical Center, Rotterdam, Netherlands, ²Department of Internal Medicine, Groningen Medical Center, Groningen, Netherlands
*Purpose: To investigate the effect of mycophenolate mofetil (MMF) on SARS-CoV-2 vaccination response in kidney transplant recipients using the standard immunosuppressive regimen of tacrolimus (TAC)…
2022 American Transplant Congress
A Single-Center’s Outcomes of Combined Heart-Liver Transplantation
R. W. Lincoln¹, K. Kalvakuri², A. Guha², A. Bhimaraj², E. E. Suarez², A. Saharia³, C. M. Mobley³, F. Amirkhosravi³, J. Krisl¹
¹Pharmacy, Houston Methodist Hospital, Houston, TX, ²DeBakey Heart and Vascular Associates, Houston Methodist Hospital, Houston, TX, ³Surgery, Houston Methodist Hospital, Houston, TX
*Purpose: The purpose of this study was to evaluate rejection outcomes in our combined heart-liver transplant (CHLT) recipients at 6 months.*Methods: This is a retrospective,…
2022 American Transplant Congress
SARS-CoV-2 Antibody Response by mRNA Vaccine Platform in Incrementally Immunosuppressed Patients
J. Mitchell¹, C. Connolly¹, T. Chiang¹, J. Alejo¹, W. Werbel¹, D. Segev¹, A. Massie²
¹Johns Hopkins University, Baltimore, MD, ²Johns Hopkins School of Medicine, Baltimore, MD
*Purpose: This study compares SARS-CoV-2 antibody responses between the two-dose mRNA-1273 and BNT162b2 vaccine series across groups of incrementally immunosuppressed patients.*Methods: Semiquantitative testing for antibodies…
2022 American Transplant Congress
Understanding The Modification Of Eplet Mismatch Risk By Immunosuppression Regimen
A. Johnson¹, X. Zhang¹, L. Gragert², C. Larsen¹
¹Emory University School of Medicine, Atlanta, GA, ²Tulane University School of Medicine, New Orleans, LA
*Purpose: Solid organ transplant donor-recipient eplet mismatch has been correlated with subsequent donor specific antibody (DSA) formation, antibody mediated rejection, and overall rejection rates. However,…
2022 American Transplant Congress
BK Viremia in Living vs Deceased Donor Renal Transplant Recipients Receiving Alemtuzumab Induction
J. P. Casale¹, D. Pluckrose¹, A. Haririan², T. Sparkes¹
¹University of Maryland Medical Center, Baltimore, MD, ²Univ of Maryland Schl of Med, Baltimore, MD
*Purpose: There is conflicting data regarding the association of donor type and BK viremia in renal transplant recipients. This study sought to compare the incidence…
2022 American Transplant Congress
Impact of Belatacept on Clinical Outcomes in Lung Transplant Patients with Antibody-Mediated Rejection
L. Zaffiri, R. Hallak, S. Leonard, M. Neely, A. Hulber, H. Berry, K. A. Young, J. M. Reynolds
Duke University, Durham, NC
*Purpose: Antibody-mediated rejection (AMR) is cause of significant morbidity and mortality in lung transplant recipients (LTRs). An optimal therapeutic regimen is still lacking. Recent evidence…
2022 American Transplant Congress
Induction of Tacrolimus Clearance by Steroids Varies by Cyp3a5 Genotype in Kidney Transplant Recipients: A Drug-Drug-Gene Interaction
P. A. Jacobson¹, A. Saqr¹, M. Al-Kofahi¹, D. P. Schladt², W. Guan³, W. S. Oetting¹, R. Mannon⁴, C. R. Dorr⁵, R. P. Remmel¹, G. C. Onyeaghala⁶, B. Wu³, A. K. Israni⁷, A. Matas⁸
¹Univ of MN, College of Pharmacy, Minneapolis, MN, ²Hennepin Health Research Institute, Minneapolis, MN, ³Univ of MN, Biostatistics, Minneapolis, MN, ⁴Univ of Nebraska, Dept of Medicine, Omaha, NE, ⁵Hennepin Health Research Institute and Dept of Medicine, Minneapolis, MN, ⁶Hennepin Healthcare Research Institute, Minneapolis, MN, ⁷Hennepin Health Dept of Medicine and Univ of MN, Minneapolis, MN, ⁸University of MN, Dept of Surgery, Minneapolis, MN
*Purpose: Tacrolimus (TAC) is the primary immunosuppressant used in organ transplantation. TAC is a substrate for CYP3A4/5. These enzymes are inhibited or induced by multiple…
2022 American Transplant Congress
Viral-Specific Cytotoxic T-Cell Responses in Hla-Sensitized Kidney Transplant Patients Maintained on Everolimus and Low Dose Tacrolimus
R. Zhang¹, S. Ge¹, M. Chu¹, J. Kahwaji², A. Karasyov¹, D. Lovato¹, A. Vo², J. Choi², M. Toyoda¹, S. Jordan²
¹Transplant Immunology Laboratory, Cedars Sinai Medical Center, Los Angeles, CA, ²Comprehensive Transplant Center, Cedars Sinai Medical Center, Los Angeles, CA
*Purpose: Post-transplant immunosuppression with “everolimus + reduced dose tacrolimus” (Ev + Taclow) is reported to reduce the risk of viral infections compared to standard doses…